Novo Nordisk a Danish pharmaceutical company specialized in diabetes care medications and devices just released their Q3 figures.
The highlights:
- Net Sales +2%
- Gross profit +1%
- Net profit +2%
- Earnings per share +5%
- Outlook FY 2017 between 3%-6% net profit increase